ArticleMedicine2026
The association between blood eosinophil count and clinical outcomes during inhaled corticosteroid/long-acting β2-agonist treatment in stable-phase chronic obstructive pulmonary disease: A retrospective cohort analysis.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Blood eosinophil (EOS) count has emerged as a potential biomarker associated with inhaled corticosteroid (ICS) responsiveness in chronic obstructive pulmonary disease (COPD). However, the relationship between EOS counts and clinical outcomes during ICS treatment in stable-phase COPD remains unclear. This study aimed to evaluate the association between baseline EOS counts and changes in lung function, symptom burden, and exacerbation frequency during ICS/long-acting β2-agonist (LABA) treatment. A retrospective cohort study included 200 stable-phase COPD patients treated with ICS/LABA combinations for 12 months. Participants were stratified into low (<150 cells/μL), medium (150-300 cells/μL), and high (>300 cells/μL) EOS groups. Outcomes included changes in forced expiratory volume in 1 second (FEV1%pred), COPD Assessment Test scores, 6-minute walk distance, and annualized exacerbation rates. Inflammatory markers (interleukin-5 [IL-5], eosinophil cationic protein) were analyzed. Baseline EOS counts were positively correlated with IL-5 and eosinophil cationic protein. After 12 months, higher baseline EOS counts were associated with greater changes in FEV1%pred and 6-minute walk distance. The reduction in exacerbation rates was 51.9% in the high EOS group versus 22.3% in the low EOS group. Receiver operating characteristic analysis identified a baseline EOS cutoff of 285 cells/μL for predicting FEV1%pred improvement ≥5%. Higher baseline EOS counts are associated with greater improvements in clinical outcomes during ICS/LABA therapy in stable COPD, although the absence of a non-ICS comparator precludes causal inference. These findings support further investigation of EOS-guided treatment strategies in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.